共 50 条
- [1] Pharmacokinetics (PK) of etanercept are unaltered by concurrent administration of methotrexate (MTX) in rheumatoid arthritis (RA) patients. [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S139 - S139
- [2] Effects of renal insufficiency on pharmacokinetics of methotrexate (MTX) in rheumatoid arthritis (RA) patients. [J]. ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 382 - 382
- [3] EFFECTS OF ETODOLAC ON METHOTREXATE (MTX) PHARMACOKINETICS IN RHEUMATOID-ARTHRITIS (RA) PATIENTS [J]. ARTHRITIS AND RHEUMATISM, 1992, 35 (09): : S343 - S343
- [4] Folic acid alters methotrexate (MTX) disposition in rheumatoid arthritis (RA) patients. [J]. ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S76 - S76
- [5] Treatment of interleukin-1 receptor antagonist in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients. [J]. ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S273 - S273
- [7] Cellcept® (mycophenolate mofetil MMF) and methotrexate (MTX):: Safety and pharmacokinetic (PK) interaction study in rheumatoid arthritis patients. [J]. ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S83 - S83
- [8] ASSOCIATION OF METHOTREXATE (MTX) AND STEROIDS IN THE TREATMENT OF RHEUMATOID-ARTHRITIS (RA) PATIENTS [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (09): : 1280 - 1280